Insights into the future digital health landscape

In the "Top of Mind for Top U.S. Health Systems 2018" report, survey results from more than 20 U.S. executives provided a look into how healthcare professionals are prioritizing health information technology trends.

The report covers priorities such as cybersecurity, predictive analytics, technology, virtual care and artificial intelligence (AI).

Findings of the report include:

  • Nine of 10 health systems reported they will increase spending on cybersecurity technology.
  • Two-thirds of respondents said they are increasing non-C suite cybersecurity staff.
  • Only 17 percent of respondents believed wearables to create valuable patient-generated data; 21 percent believe the same for mobile health apps.
  • Over half of respondents were using or plan to use genomic testing as part of providing personalized medicine.
  • 39 percent of respondents received reimbursement for virtual care, and 45 percent receive reimbursement for remote monitoring.
  • Of the respondents not receiving reimbursement, 71 percent expect to in 2018.
  • Implementation of AI ranked low or very low in two-thirds of the responding health systems, because of the difficulty in proving its value while it is still in its early stages.
""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.